Perm scientists presented «Diphage» - innovational complex product to treat nosocomial infections
At the latest interregional scientific and practice conference "Providing epidemiology safety in surgical hospitals and ICU" Perm scientists presented their project of producing innovational complex prouct "Diphage", based on Acinetobacter baumannii and Pseudomonas aeruginosa. These microorganisms often cause infectious diseases at surgical hospitals and ICU. Research studies were made by the specialists of Perm Subsidiary ”Perm SIC ”Biomed” in collaboration with the specialists of Saint-Petersburg Medical Academy.
The specialists of Perm Subsidiary ”Perm SIC ”Biomed” make a point that "Diphage" development is particularly important. Today Acinetobacter baumannii and Pseudomonas aeruginosa are the infectious agents of high variety of nosocomial infections and have extensive resistance to antibiotics of different classes.
Working on "Diphage" the specialists selected strains of Acinetobacter baumannii and Pseudomonas aeruginosa from a number of laboratories in Moscow, Saint-Petersburg, Perm, Ekaterinburg and Minsk and studied their biological characteristics. That way they found out some phage races with lytic activity against the infectious agents and also improved the technology of producing "Diphage", studied its safety, specific activity, range and other parameters that were necessary for commissioning. Product efficacy studies that took place at the clinical sites, demonstrated high sensitivity to a batch of "Diphage" and at the same time extraordinary antibiotic resistance. That means "Diphage" can be used not only to treat but also to prevent zymosis.
At this point preclinical tests have been successfully completed.
The specialists at the conference admitted that the phages of "Microgen" can help to solve the problem of antibiotic resistance. Bacteriophages affects only vulnerable cells causing their death but don't harm normal microflora. In some cases phages monotherapy might be a good alternative to antibiotics.
”Perm SIC ”Biomed” has been manufacturing bacteriophage products since 1995. Nowadays it has a unique collection of microorganisms and phages and works on improvement of technological aspects of manufacturing, including new dosage forms.
Currently "Microgen" carries out the procedure of joining the pharmaceutical holding company "National Immunobiological Company" (NIC) in accordance with the Edict of the President of the Russian Federation No. 139 of 17.03.2015.
NIC is a part of Rostec State Corporation, it was founded in 2013 as a pharmaceutical holding company in the field of developing and producing immunobiological products. The main purpose is to eliminate dependence of the Russian Federation from imported medical products such as immunobiological products and products treating infectious deseases by developing its own manufacturing and research capacities. In accordance with its strategy up to 2020 holding company is going to satisfy in full the national requirement for vaccines for the national vaccination schedule.